Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:19:06.044Z.
Calculation as of: 2026-10-06T18:19:06.044Z.
Quote observation: 2026-10-06T18:14:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8bdc5b92b4d262cc13a98cf6604682d0e20af2b1e6f35657b788ee16300fad7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Talphera, Inc.
Market Cap
$57.09M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Talphera, Inc. (TLPH) | $57.09M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $57.32M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $57.69M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.05M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.78M | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $54.50M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
